Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akumin Inc. stock logo
AKU
Akumin
$0.18
$0.12
$1.90
$26.32M-0.721.38 million shs8.54 million shs
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$3.69
-1.3%
$4.25
$2.45
$5.55
$385.24M1.34630,860 shs429,334 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akumin Inc. stock logo
AKU
Akumin
0.00%0.00%0.00%0.00%-53.44%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-1.58%-5.08%-14.02%-26.67%-20.43%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akumin Inc. stock logo
AKU
Akumin
N/AN/AN/AN/AN/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
1.8971 of 5 stars
3.52.00.00.01.12.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akumin Inc. stock logo
AKU
Akumin
1.50
Reduce$0.25∞ Upside
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.00
Buy$8.67134.87% Upside

Current Analyst Ratings

Latest MXCT, AKU, and YGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$11.00
3/13/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
3/13/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$11.00
3/13/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/5/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akumin Inc. stock logo
AKU
Akumin
$749.63M0.00N/AN/A$1.24 per share0.00
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$41.29M9.33N/AN/A$2.23 per share1.65

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akumin Inc. stock logo
AKU
Akumin
-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$37.92M-$0.37N/AN/AN/A-91.85%-15.90%-13.94%5/7/2024 (Confirmed)

Latest MXCT, AKU, and YGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.14N/A+$0.14N/AN/AN/A  
3/12/2024Q4 2023
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.10-$0.05+$0.05-$0.05$15.60 million$15.67 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akumin Inc. stock logo
AKU
Akumin
N/AN/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akumin Inc. stock logo
AKU
Akumin
17.02
0.99
0.99
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/A
10.65
9.97

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akumin Inc. stock logo
AKU
Akumin
36.10%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
68.81%

Insider Ownership

CompanyInsider Ownership
Akumin Inc. stock logo
AKU
Akumin
20.51%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
6.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akumin Inc. stock logo
AKU
Akumin
3,63191.17 million72.47 millionNot Optionable
MaxCyte, Inc. stock logo
MXCT
MaxCyte
143104.40 million98.13 millionOptionable

MXCT, AKU, and YGEN Headlines

SourceHeadline
MaxCyte (NASDAQ:MXCT) Receives "Overweight" Rating from StephensMaxCyte (NASDAQ:MXCT) Receives "Overweight" Rating from Stephens
americanbankingnews.com - April 24 at 5:26 AM
MaxCyte (NASDAQ:MXCT) Receives Overweight Rating from StephensMaxCyte (NASDAQ:MXCT) Receives Overweight Rating from Stephens
marketbeat.com - April 23 at 11:56 AM
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
globenewswire.com - April 10 at 8:05 AM
Mesa Laboratories maintains quarterly dividend of $0.16Mesa Laboratories maintains quarterly dividend of $0.16
msn.com - April 5 at 1:52 AM
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
globenewswire.com - April 2 at 8:05 AM
Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 5,000 Shares of StockInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 5,000 Shares of Stock
insidertrades.com - March 29 at 8:56 AM
John Joseph Johnston Sells 5,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockJohn Joseph Johnston Sells 5,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock
marketbeat.com - March 28 at 7:55 PM
Downgrade: Heres How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near TermDowngrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
finance.yahoo.com - March 17 at 8:04 AM
MaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
finanznachrichten.de - March 15 at 8:07 AM
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their EstimatesMaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
finance.yahoo.com - March 14 at 10:45 AM
MaxCyte Shares Rise 13% After 4Q Beat, Reaffirmed GuidanceMaxCyte Shares Rise 13% After 4Q Beat, Reaffirmed Guidance
marketwatch.com - March 13 at 8:22 AM
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
globenewswire.com - March 12 at 4:05 PM
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
globenewswire.com - March 12 at 4:05 PM
MaxCyte, Inc.: MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMaxCyte, Inc.: MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
finanznachrichten.de - March 6 at 4:53 PM
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
globenewswire.com - March 4 at 4:05 PM
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
globenewswire.com - March 4 at 4:05 PM
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
finance.yahoo.com - February 9 at 8:25 AM
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
finance.yahoo.com - January 30 at 9:41 AM
MaxCyte Signs SPL Agreement With ImugeneMaxCyte Signs SPL Agreement With Imugene
markets.businessinsider.com - January 23 at 1:02 PM
Why Cell Engineering Company MaxCyte Shares Are Up TodayWhy Cell Engineering Company MaxCyte Shares Are Up Today
msn.com - January 9 at 1:07 PM
COMM, NKTX and AVIR are among after hour moversCOMM, NKTX and AVIR are among after hour movers
seekingalpha.com - January 9 at 8:07 AM
MaxCyte Stock (NASDAQ:MXCT) Dividends: History, Yield and DatesMaxCyte Stock (NASDAQ:MXCT) Dividends: History, Yield and Dates
benzinga.com - January 5 at 9:06 AM
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCRs TCR-T Cell ...MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell ...
bakersfield.com - January 3 at 9:13 AM
MaxCyte teams with Singapore-based Lion to support TCR-T cell workMaxCyte teams with Singapore-based Lion to support TCR-T cell work
shareprices.com - January 3 at 9:13 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akumin logo

Akumin

NASDAQ:AKU
Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.
MaxCyte logo

MaxCyte

NASDAQ:MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.